This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Wolowacz SE, Cameron DA, Tate HC, Bagust A.Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. Journal of Clinical Oncology 26: 925-933, No. 6, 20 Feb 2008
Rights and permissions
About this article
Cite this article
Adjuvant docetaxel combo of value in early breast cancer. Pharmacoecon. Outcomes News 548, 7 (2008). https://doi.org/10.2165/00151234-200805480-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805480-00018